article
6 May 2014 | By Erik Ryberg (AstraZeneca R&D), Linda Sundström (AstraZeneca R&D), Lovisa Frostne (AstraZeneca R&D), Niklas Larsson (AstraZeneca R&D)
Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…